Opaleye Management’s X4 Pharmaceuticals XFOR Stock Holding History

Opaleye Management’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,500	Closed	-$508K	–	65
2020 Q3	$508K	Buy	+2,500	New	+$599K	0.1%	50

Other funds holding XFOR

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Opaleye Management's XFOR Position: Q4 2020 in Review

Opaleye Management sold out of X4 Pharmaceuticals (XFOR) in Q4 2020, closing a stake of 2,500 shares — an estimated $508K sold.

Opaleye Management first reported a position in XFOR in Q3 2020 and held it in 1 quarter. The position peaked at $508K in Q3 2020. 53 funds tracked by Wall St. Rank hold XFOR as of Q4 2020.

Opaleye Management reported no remaining X4 Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Opaleye Management sold 2,500 X4 Pharmaceuticals shares in Q4 2020, an estimated $508K.
Opaleye Management first reported a position in X4 Pharmaceuticals in Q3 2020 and held it in 1 quarter.
Opaleye Management's X4 Pharmaceuticals position peaked at $508K in Q3 2020.
53 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2020.

Based on Opaleye Management's 13F filing for Q4 2020, filed 12 Feb 2021.